CorMedix

IPO

Home - CorMedix | Prevention of cardiac, renal and infectious diseases

Public · Berkeley Heights, United States · Founded 2006 · $150.3M raised

Founded
2006
Business Model
B2B
Total Funding
$150.3M
Last Round
$150.0M Convertible NoteAug 2025
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 1 investor for this company. The full record is or through the API.

About

CorMedix (now CorMedix Therapeutics, NASDAQ: CRMD) is a biopharmaceutical company founded in 2006 and headquartered in Berkeley Heights, New Jersey. The company focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, including its lead product DefenCath (taurolidine/heparin), an FDA-approved catheter lock solution. In 2025, CorMedix acquired Melinta Therapeutics, significantly expanding its commercial antibiotic portfolio.

Summary

CorMedix is a Biotech company based in Berkeley Heights, United States, founded in 2006. It has raised $150.3M in total across 2 rounds, most recently a $150.0M Convertible Note round in Aug 2025. Investors include Deerfield Management.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

ConvertibleConvertible NoteAug 2025
$150.0M

Sign up to see all 2 events

Funding: Grant through Convertible Note. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CorMedix on Indexed.vc
<a href="https://indexed.vc/companies/cormedix"><img src="https://indexed.vc/api/badge/company/cormedix" alt="CorMedix on Indexed.vc" width="260" height="76" /></a>